

Referral Status:	MRN:
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change
<input type="checkbox"/> Order Renewal	
Patient preferred clinic:	

## Tocilizumab Unspecified Plan of Treatment for Rheumatology

### PATIENT DEMOGRAPHICS:

Date of Referral:	Patient's Phone:
Patient Name:	Address:
Date of Birth:	City, State, Zip:
Height in inches:	Weight: LB or KG
Gender:	Allergies:
<input type="checkbox"/> See list	<input type="checkbox"/> NKDA

### DIAGNOSIS: (PLEASE COMPLETE 2<sup>ND</sup> AND 3<sup>RD</sup> DIGITS TO COMPLETE ICD 10 FOR BILLING)

M05._____ - Rheumatoid Arthritis with Rheumatoid factor	M31.6 - Other Giant Cell Arteritis
M06._____ - Rheumatoid Arthritis without Rheumatoid factor	M31.5 - Giant cell Arthritis with Polymyalgia Rheumatica
_____ - Other:	

### REQUESTED DOCUMENTATION:

1	Insurance information	IF NO:	IF YES:
2	Most recent History & Physical	PLEASE STATE	LAST INFUSION DATE:
3	Full medication list / Tried and failed therapies	REQUIRED WASHOUT	NEXT INFUSION DATE:
4	<b>REQUIRED:</b> TB screening for new start	FROM PREVIOUS	<b>IF ORDER CHANGE:</b>
5	HBV screening/labs as required by payor	THERAPY:	
6	Recent CBC with diff and LFTs		<b>Continue current order until insurance approved</b>

### MEDICATION ORDERS:

#### PREMEDICATION TO BE ADMINISTERED 30 MINUTES PRIOR TO ADMINISTRATION AS SELECTED

NOTE: Patient may be ineligible to receive tocilizumab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new-onset or deterioration neurological changes, new-onset abdominal symptoms, and/or surgery.

IV	Diphenhydramine	25mg	50mg		PO	Acetaminophen	325mg	500mg	650mg	1000mg
	Methylprednisolone	40mg	125mg	Other:		Famotidine	20mg	40mg		
	Famotidine	20mg	40 mg			Diphenhydramine	25mg	50mg		
	Other:					Fexofenadine	60mg	180mg		
					Cetirizine	10mg				
					Loratadine	10mg				
					Other:					

### SPECIFIC MEDICATION:

<input type="checkbox"/>	Actemra <sup>®</sup>	<input type="checkbox"/>	<b>Any tocilizumab biosimilar may be used according to payer guidelines</b>
<input type="checkbox"/>	Tyenne <sup>®</sup>		

### DOSE: Rheumatoid Arthritis

<input type="checkbox"/>	4mg/kg in 100mL NS every 4 weeks - IV over 1 hour
<input type="checkbox"/>	8mg/kg in 100mL NS every 4 weeks - IV over 1 hour

### DOSE: Giant Cell Arteritis

<input type="checkbox"/>	6mg/kg in 100mL NS every 4 weeks - IV over 1 hour
--------------------------	---

### SPECIAL/LAB ORDERS:

<input type="checkbox"/>	
--------------------------	--

### LAB ORDERS:

**CBC with diff, platelets, ALT and AST prior to first dose, at 2nd infusion, and then every 12 weeks.**

### LAB PARAMETERS: (Pharmacist to perform clinical lab monitoring)

On Initiation: ANC > 2000/mm<sup>3</sup>; AST/ALT < 1.5 x ULN  
 Maintenance: **If ANC** is 500 to 1000 cells/mm<sup>3</sup>, hold dose and notify referring MD. When ANC > 1000 cells/mm<sup>3</sup> therapy may be resumed. **If ANC** < 500 cells/mm<sup>3</sup>, then discontinue and notify referring MD. **If Platelet count** 50,000 to 100,000 cells/mm<sup>3</sup>, hold dose. When platelet count is > 100,000 cells/mm<sup>3</sup>, therapy may be resumed. **If Platelet count** is < 50,000 cells/mm<sup>3</sup>, then discontinue and notify referring MD. **If AST/ALT** are > 3-5 x upper limit normal HOLD dose and notify referring MD

**Tocilizumab doses exceeding 800mg are not recommended.**

Prescriber confirms that the patient has been evaluated and screened for the presence of hepatitis B virus (HBV) prior to initiating treatment.  
 Prescriber to monitor patient for symptoms of HBV and TB infection and reactivation as clinically appropriate.

<input checked="" type="checkbox"/>	Refills x 12 months unless noted otherwise here:
-------------------------------------	--

### LINE USE/CARE ORDERS:

<input checked="" type="checkbox"/>	Start PIV/Access CVC
<input checked="" type="checkbox"/>	Flush device per facility standard flushing procedure
<input checked="" type="checkbox"/>	Provide nursing care per Palmetto Infusion Nursing Procedures and post procedure observation if indicated

### ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website or scan here.



### PRESCRIBER INFORMATION:

PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:

### PRESCRIBER SIGNATURE: (No stamp signatures)

### DATE

Dispense as written/Brand medically necessary	Substitution permitted	



## Checklist for referrals to Palmetto Infusion: Fax referral to 1.866.872.8920

- Patient demographics - address, phone number, SS#, etc.**
- Insurance information - copy of the card(s) if possible**
- Plan of Treatment/Orders**
- Most recent physician office notes to include tried and failed therapies - all insurance companies that require a pre-authorization require the note. This includes Medicare/Medicaid HMOs.**
- Any lab results or other diagnostic procedures to support the diagnosis.**

Palmetto Infusion will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility.

Our office will notify you if any further information is required.

We will review financial responsibility with patient and refer them to any available co-pay assistance as required. Palmetto Infusion Call Center 800.809.1265. Thank you for your referral.

[www.PalmettoInfusion.com](http://www.PalmettoInfusion.com)